Skip to content

Posts by Immunexpress

SeptiCyte™ LAB Differentiates Sepsis from SIRS in the ICU

Immunexpress.com

Design and results of clinical trials that led to FDA clearance of SeptiCyte™ LAB published in the American Journal of Respiratory and Clinical Care Medicine SEATTLE, May 9, 2018 /PRNewswire/ — Immunexpress, Inc. today announced the publication in the American Journal of Respiratory and Clinical Care Medicine of the design and results of clinical trials validating SeptiCyte™ LAB in the…

Read More

Immunexpress and Academic Medical Center to Collaborate on Development of Sepsis-Related Biomarker Panels

Immunexpress.com

SEATTLE, April 19, 2016 — Immunexpress Inc. today announced an exclusive collaboration with the Academic Medical Center (AMC) at the University of Amsterdam to characterize and clinically evaluate sepsis and sepsis-related biomarker signatures of the host response. This four-year collaboration with AMC’s Prof. Dr. Tom van der Poll and his team will leverage the informatics expertise…

Read More

Immunexpress Presents on the Need for an Objective Diagnostic Tool for Systemic Inflammation at the International Symposium on Intensive Care and Emergency Medicine

Immunexpress.com

Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, today announced the presentation of data from the VENUS trial by Dr. Bert Lopansri of Intermountain Medical Center at the 36th International Symposium on Intensive Care and Emergency Medicine in Brussels, Belgium. The presentation describes the diagnostic variability observed between physicians…

Read More

Immunexpress Announces Presentation at the 36th International Symposium on Intensive Care and Emergency Medicine on the Need for an Objective Diagnostic Tool for Systemic Inflammation

Immunexpress.com

Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, today announced that data from the VENUS trial showing the discordance between clinical impressions of patients with systemic inflammation will be presented at the upcoming 36th International Symposium on Intensive Care and Emergency Medicine on Mar. 15 in Brussels, Belgium. Poster…

Read More

Immunexpress Secures U.S. Patent for Immune Biomarkers for Herpes Virus Infection

Immunexpress.com

Immunexpress Secures U.S. Patent for Immune Biomarkers for Herpes Virus Infection SEATTLE, United States (November 21, 2012) – Today, Immunexpress Group announced the granting in the United States (U.S.) of one of its core biomarker patents, “microarray-mediated diagnosis of herpes virus infection by monitoring host’s differential gene expression upon treatment.” The patent covers host response…

Read More

Immunexpress Announces New Collaboration with MARS Consortium to Improve Care of Sepsis Patients

Immunexpress.com

Immunexpress Announces New Collaboration with MARS Consortium to Improve Care of Sepsis Patients The MARS Consortium is one of the largest collaborations of academic and industry partners dedicated solely to improving sepsis outcomes SEATTLE, United States / EINDHOVEN, The Netherlands (April 10, 2013) –Today, the Immunexpress Group announced its collaboration with the Molecular Diagnosis and…

Read More

Immunexpress Secures New EU Patent for Immune Biomarkers for Herpes Virus Infection

Immunexpress.com

Immunexpress Secures New EU Patent for Immune Biomarkers for Herpes Virus Infection April 1, 2013 – Today, Immunexpress Group announced the granting of one of its core biomarker patents, “microarray-mediated diagnosis of herpes virus infection by monitoring host’s differential gene expression upon treatment” in the European Union (EU). This patent compliments the U.S. herpes virus…

Read More

Immunexpress Receives Early Stage Commercialisation Support to Further Develop SeptiCyte® PLUS

Immunexpress.com

Immunexpress receives Early Stage Commercialisation support to further develop SeptiCyte®PLUS — designed to diagnose sepsis accurately within a clinically relevant timeframe. BRISBANE, Australia (February 18, 2014) – Today, Immunexpress Group (Immunexpress) announced it has received Early Stage Commercialisation support through Commercialisation Australia, an initiative of the Australian Government. The AUD $982,707 grant will support the…

Read More

Immunexpress to Present Data on Utility of SeptiCyte™ LAB for Diagnosing Sepsis at the Pathology Diagnostics Conference

Immunexpress.com

Immunexpress to Present Data on Utility of SeptiCyte™ Lab for Diagnosing Sepsis at the Pathology Diagnostics Conference SeptiCyte™ Lab Quantifies Host Molecular Markers to Aid Physicians in the Diagnosis of Sepsis in Critical Care Patients SEATTLE, June 4, 2015 – Immunexpress, Inc. today announced that Dr. Antony Rapisarda, Director Medical Affairs, will present data at…

Read More

Immunexpress to Present Data on the Early Diagnosis of Sepsis with SeptiCyte™ LAB at the Next Generation Diagnostics Summit

Immunexpress.com

SEATTLE, Aug. 12, 2015 – Immunexpress, Inc. today announced that Dr. Therese Seldon, Vice President of Operations, will present data on the utility of its SeptiCyte® Lab test to aid in the clinical assessment of sepsis in critical care patients at the Next Generation Diagnostics Summit on Aug. 19 in Washington, D.C. The presentation will…

Read More
Scroll To Top